How Effective Are Allergy Shots? What the Evidence Shows

Allergy shots significantly outperform placebo in controlled clinical trials. The Calderon et al. Cochrane meta-analysis (2007), which synthesized 51 double-blind, placebo-controlled trials involving 2,871 patients, found a pooled standardized mean difference (SMD) of -0.73 for symptom reduction and -0.57 for medication use reduction — both highly statistically significant (P<0.00001). These are not small effects: an SMD of 0.73 is considered a moderate-to-large effect in medical research. Importantly, placebo-controlled trials used genuine sham injections, ruling out placebo response as an explanation for the observed benefits. Roughly 50-80% of patients in real-world settings achieve clinically meaningful improvement. The number needed to treat (NNT) for symptom benefit is approximately 3, meaning for every 3 patients treated, 2 see significant improvement.

Allergy shots work best for IgE-mediated (true allergic) conditions, but effectiveness varies significantly by the specific allergen. The evidence is strongest for grass pollen, house dust mites, and ragweed — these allergens have the most robust randomized controlled trial data supporting SCIT. Moderate evidence exists for cat dander, birch pollen, and Alternaria mold. Weaker evidence exists for dog dander, and the most rigorous recent cockroach SCIT trial (CRITICAL, 2024) failed its primary clinical endpoint despite immunologic changes. SCIT does not work for non-allergic rhinitis, vasomotor rhinitis, or food allergies, as these conditions are not driven by the IgE-mediated pathway that immunotherapy targets. A board-certified allergist can assess whether your specific allergen profile makes you a good candidate.

Most patients begin noticing symptom improvement within 6-12 months of starting allergy shots, though some may notice early changes during the build-up phase (months 3-6). Full benefit typically requires completing at least 3 years of treatment, including both the build-up and maintenance phases. The treatment timeline reflects the biological process: immune retraining — shifting from an allergic (Th2-dominant) to a tolerant response — takes months to years to fully establish. Studies show that patients who complete 3 or more years of maintenance have significantly better long-term outcomes than those who discontinue early. The EAACI guidelines state explicitly that at least 3 years is required to achieve sustained post-discontinuation efficacy. Patients who stop after 1-2 years often experience symptom relapse, because the immune tolerance has not been sufficiently consolidated.

Based on clinical trial and real-world data, approximately 50-80% of allergy shot patients achieve clinically meaningful improvement. Lee et al. (2018) followed 304 adults receiving house dust mite SCIT and found cumulative clinical remission of 76.6% at a mean of 4.9 years. A prospective Beijing HDM-SCIT cohort reported 57.4% high responders versus 42.6% low or non-responders at 3 years. The remaining 20-50% who don't achieve full improvement often have identifiable, potentially addressable reasons: wrong allergen identification, subtherapeutic dosing, or premature discontinuation. Predictors of better response include monosensitization (allergy to one allergen), younger age at treatment start, shorter disease duration, and high baseline specific IgE levels.

Allergy shots do not 'cure' allergies in the sense of eliminating all immune memory of allergens. However, they produce durable disease modification that can persist many years after stopping treatment. Durham et al. (N Engl J Med, 1999) demonstrated that patients who completed 3-4 years of grass SCIT maintained significantly lower symptom and medication scores for at least 3 years after discontinuation, indistinguishable from those who continued treatment. Eng et al. (Allergy, 2006) confirmed this benefit extended to 12 years post-treatment in a pediatric cohort. Some patients do experience symptom relapse over time and may need a second course. A second course typically works faster than the first, since some immunologic memory persists from the initial treatment.

Whether allergy shots are worth the time investment depends on several factors: the severity of your symptoms, your specific allergens, how much your allergies affect your quality of life, and your ability to commit to the schedule. The time investment is substantial — roughly 57-60 clinic visits over 3 years, totaling approximately 110 hours including travel and post-injection observation. Cost-effectiveness analyses generally support immunotherapy: Hankin et al. (2010) found 18-month healthcare costs were 33% lower for patients receiving immunotherapy versus matched controls, with savings emerging within 3 months. Long-term, the disease-modifying benefit — reduced or eliminated need for daily medications, reduced asthma risk in children, prevention of new sensitizations — often outweighs the short-term burden. Patients with mild, seasonal allergies who respond well to antihistamines may find the commitment less justified.

Clinical evidence suggests allergy shots may reduce the risk of asthma developing in children with allergic rhinitis, though this benefit is not proven at the highest level of evidence in randomized controlled trials. The Prevention of Allergy Treatment (PAT) study (Moller et al., JACI, 2002) found that children receiving 3 years of SCIT for grass and birch pollen allergic rhinitis had significantly lower rates of asthma development during treatment. Jacobsen et al. (Allergy, 2007) followed these same children at 10 years post-treatment and found an odds ratio of 2.5 favoring SCIT for asthma prevention — meaning SCIT-treated children were 2.5 times more likely to remain asthma-free. Approximately 5-6 children would need to be treated to prevent one new asthma case. However, the PAT study was not blinded for the control arm, which limits its evidence grade.

Intranasal corticosteroids like fluticasone or mometasone reduce nasal symptom scores by approximately 31.7%, while allergy shots reduce them by approximately 34.7%, according to the Matricardi et al. indirect meta-analytic comparison (JACI, 2011). So on immediate symptom relief, these treatments are broadly comparable. The critical difference is what happens long-term. Nasal sprays require daily use and stop working as soon as you stop using them — they do not modify the underlying immune response. Allergy shots, after a complete 3-5 year course, produce disease modification that persists for years after stopping. They can also reduce new sensitizations and lower asthma risk in children. For patients with moderate-to-severe persistent allergic rhinitis who want to eventually reduce or stop medication use, allergy shots offer a fundamentally different outcome trajectory.

If you complete a full course of allergy shots (typically 3-5 years), the disease-modifying benefits generally persist for several years after stopping. The landmark study by Durham et al. (N Engl J Med, 1999) showed no significant difference in symptom or medication scores between patients who continued maintenance and those who stopped after 3-4 years, for at least 3 subsequent allergy seasons. Eng et al. (Allergy, 2006) extended this finding to 12 years in a pediatric cohort — former SCIT patients still had significantly lower symptom scores and medication use than untreated controls. The general estimate from the evidence is 3-12 years of post-treatment benefit, depending on treatment duration, allergen type, age of the patient, and whether they were monosensitized. Patients who stop before completing 3 years are much more likely to relapse.